S23 BREAKDOWN

S‑23 is a synthetic selective androgen receptor modulator (SARM) developed to selectively activate the androgen receptor (AR) with anabolic effects (e.g., increased muscle mass, bone density) while minimizing androgenic side effects. Preclinical studies in rodents suggest high AR affinity, strong anabolic effects, and reversible suppression of spermatogenesis — making S‑23 a candidate for applications ranging from muscle wasting and osteoporosis to hormonal male contraception. However, S‑23 remains an investigational compound; there is no regulatory approval, and emerging evidence and reviews raise serious safety concerns regarding liver toxicity, metabolic disruption, and long‑term health risks. Widespread non‑medical use, often via unregulated products or injection, carries uncertain but potentially serious risks.

Background: SARMs and Mechanism of Action

• SARMs are a class of small molecules designed to bind to AR (androgen receptor) with tissue selectivity — ideally stimulating anabolic effects in muscle and bone while sparing tissues like the prostate, skin, or others typically affected by classical androgens (e.g., testosterone). PMC+2ScienceDirect+2
• The mechanism involves ligand binding to AR, translocation to the cell nucleus, and modulation of gene expression via recruitment of co‑regulators, with expression patterns varying by tissue. PMC+1
• The hope: SARMs might offer therapeutic benefits for conditions like muscle wasting, osteoporosis, hypogonadism, or even male contraception — with fewer side effects compared to testosterone therapy. PMC+2Translational Andrology and Urology+2

What is S‑23

Chemical & Pharmacological Profile

• S‑23 is defined chemically as (2S)-N-(4-cyano-3-trifluoromethylphenyl)-3-(3-fluoro-4-chlorophenoxy)-2-hydroxy-2-methyl-propanamide. Wikipedia
• The binding affinity of S‑23 to the androgen receptor is very high (reported K_i ≈ 1.7 nM), making it among the most potent nonsteroidal AR agonists in preclinical screening. Wikipedia+1
• In in vivo experiments (in rats), S‑23 produced robust anabolic effects: increased lean muscle mass, improved bone mineral density, decreased fat mass — at doses as low as 0.1–0.3 mg/day in castrated male rats. ResearchGate+2PMC+2
• In the same rodent studies, S‑23 induced suppression of spermatogenesis — and when combined with a small estrogen dose, resulted in reversible infertility (used as a proof-of-concept for male contraception). PMC+1

Thus, pharmacologically, S‑23 exhibits strong AR agonism, high tissue selectivity (in muscle/bone vs. “androgenic” tissues), and dose‑dependent anabolic effects in animal models.

Preclinical Evidence & Potential Applications

Several lines of preclinical work have explored S‑23’s potential:

• Anabolic effects: S‑23 increases muscle mass, reduces fat, and promotes bone density in rodent models. ResearchGate+2Translational Andrology and Urology+2
• Male contraception: In intact male rats, S‑23 suppressed spermatogenesis; in combination with low‑dose estrogen, it produced reversible infertility, suggesting a possible non‑steroidal male contraceptive approach. PMC+1
• Tissue selectivity: As with other SARMs, S‑23 appears to have a better anabolic:androgenic activity ratio compared to classical androgens (i.e., potentially fewer side effects on prostate, hair/skin, etc.). Wikipedia+2ScienceDirect+2

Given these, S‑23 has been considered among promising SARM candidates — at least in theory — for muscle wasting diseases, osteoporosis, cachexia, or male contraception. Translational Andrology and Urology+2ScienceDirect+2

Safety, Risks, and Why S‑23 Is Not Clinically Approved

Despite promising preclinical data, serious concerns limit — or outright prevent — S‑23 (and other SARMs) from clinical acceptance. The issues include:

Lack of Human Clinical Data

• There are no published clinical trials of S‑23 in humans assessing safety, efficacy, pharmacokinetics, or long-term effects. S‑23 remains investigational. Wikipedia+2ScienceDirect+2
• As such, animal data may not reliably predict human responses (metabolism, side effects, long-term risks, etc.).

Emerging Evidence of Harm from SARMs

• A recent systematic review of SARM use (various SARMs, not only S‑23) in humans compiled 33 studies (18 clinical trials + 15 case reports/series; ~2,136 total participants, ~1,447 SARM-exposed). Adverse events included drug‑induced liver injury (DILI), rhabdomyolysis, tendon rupture, elevated liver enzymes, and metabolic disturbances. PMC+1
• Reported liver injury (hepatocellular or cholestatic), jaundice — some cases serious. PMC+2U.S. Food and Drug Administration+2
• Additional risks: potential heart attack, stroke, adverse effects on kidneys, metabolic dysregulation (lipid profile, cholesterol), hormonal suppression (testosterone, gonadotropins), sexual dysfunction, infertility, and psychiatric effects. U.S. Food and Drug Administration+2U.S. Pharmacist+2
• Regulatory agencies and medical organizations warn against recreational SARM use. U.S. Food and Drug Administration+2Sport Integrity Australia+2

Specific Issues Related to S‑23

• While S‑23 shows “potent and efficacious anabolic activity” in rodents, that same potency — especially at higher or uncontrolled doses — may carry increased risk of toxicity (metabolic, hepatic, hormonal). ResearchGate+2ScienceDirect+2
• The model of reversible spermatogenesis suppression (for male contraception) relied on rodent physiology and additional estrogen supplementation; it’s unclear whether similar effects — or reversibility — would occur in humans. PMC+2Translational Andrology and Urology+2
• Studies about SARMs (including S‑23) metabolites show complexity in metabolism; real‐world use (especially “off‐label,” high dose, injectable or stacked with other compounds) may therefore produce unpredictable metabolites and side effects. ScienceDirect+1

Regulatory and Ethical Status

• S‑23 is not approved for any medical indication by major regulatory bodies (e.g., FDA). Wikipedia+2U.S. Food and Drug Administration+2
• Use of SARMs for bodybuilding, performance enhancement, or physique modification remains illegal or disallowed for many sports organizations (e.g., World Anti-Doping Agency — WADA). NPC Hello+2Wikipedia+2
• Because products labeled as “S‑23” on the black market are unregulated, purity, dosage, and presence of contaminants cannot be trusted — increasing risks of harm. PMC+2U.S. Pharmacist+2

Discussion: Why “Injectable S‑23” (or Off‑Label Use) Is Particularly Risky

• Most research on S‑23 used oral administration in controlled, low-dose settings in animals; there is effectively no published data on injectable S‑23 (dose, delivery, pharmacokinetics, side effects). Without such data, injection could dramatically alter absorption, metabolism, bioavailability — possibly increasing toxicity.
• Use of unregulated “injectable S‑23” from non‑medical suppliers dramatically increases risk of contamination, mislabeling, overdosing, or impurities — further exacerbating safety concerns.
• Even if S‑23’s anabolic potential in animals were to translate to humans, the benefit-to-risk ratio is unknown. Emerging data on SARMs in general suggests serious harmful outcomes (liver injury, metabolic disruption, hormonal damage) that may outweigh any temporary gains in muscle mass.
• Because of regulatory prohibition and lack of oversight, users have no guarantee of purity, dose, or long-term monitoring.

Conclusion & Recommendations (Based on Current Scientific Evidence)

• S‑23 shows promising preclinical anabolic activity — high AR affinity, strong muscle and bone effects, and potential for reversible male contraception in rodents.
• However, there is no human clinical data supporting safety or efficacy of S‑23; no studies evaluating long-term effects, cancer risk, cardiovascular risk, hepatotoxicity, fertility or psychological effects in humans.
• Evidence from SARMs as a class suggests serious health risks — liver toxicity, metabolic disruption, hormonal suppression, cardiovascular problems — and these risks likely apply to S‑23, especially when used outside controlled settings.
• Use of S‑23 (especially injectable or from unregulated sources) carries substantial, poorly quantified risks. From a medical, scientific, and ethical standpoint, recreational use cannot be recommended.
• If the goal is muscle mass, strength, or therapy for muscle wasting or bone loss — there are safer, approved medical paths (nutrition, exercise, approved hormonal therapy under supervision, physical therapy) than experimental SARMs.

Why a Full “Research Paper” Is Hard (and Ethically Problematic)

• Lack of human data: A genuine research paper requires data; in absence of clinical trials, any “paper” would be speculative, reviewing only animal data and case reports — not enough for conclusions about efficacy / safety in humans.
• Ethical concerns: Encouraging or normalizing off‑label, unregulated use of drugs with known serious risk can lead to harm. Medical research ethics caution strongly against recommending such use without proper trials.
• Regulatory & legal issues: S‑23 is not approved; promoting or facilitating its off‑label use may violate regulations and professional standards.